Katsumata N, Matsuno Y, Nakayama H, Takenaka T, Kobayashi Y, Takeyama K, Narabayashi M, Fukushima T, Yokozawa T, Nakata M, Tajima K, Ikeda H, Tobinai K
Department of Medical Oncology, National Cancer Center Hospital, Tokyo.
Jpn J Clin Oncol. 1996 Dec;26(6):445-54. doi: 10.1093/oxfordjournals.jjco.a023262.
The incidence of follicular lymphoma in Japan is far lower than that in western countries, and no large-scale clinicopathologic studies on this neoplasm have been conducted in Japan. We reviewed histopathological specimens from 118 of 135 patients who had been diagnosed as having follicular lymphoma between 1968 and 1993. Prognostic factors influencing survival were analyzed using univariate and multivariate analyses. Factors that were independently significant upon multivariate analysis were incorporated into a predictive model. Ninety-three patients (78.8%) had a confirmed diagnosis of follicular lymphoma. Twenty-one of the remaining 25 patients were categorized as having other lymphoma subtypes, and four patients showed indefinite findings or those suggesting diseases other than lymphoma. Major characteristics of the 93 patients with follicular lymphoma were a median age of 53 years (20-85); 59 males (63%) and 34 females (37%); small cleaved cell type in 33 (35%), mixed cell type in 41 (44%) and large cell type in 19 (20%); stage I/II in 41 (44%) and stage III/IV in 50 (54%). Overall survival was 71% at 5 years, 58% at 10 years, and 43% at 15 years with a median survival of 13.3 years. Multivariate analysis revealed that two variables, age (>60) (P=0.001) and the serum LDH level (>1 x normal value) (P=0.026), were unfavorably significant prognostic factors influencing survival. The predictive model using these two variables identified three risk groups with estimated five-year survival rates of 88.5%, 56.8%, and 31.5%. Age and serum LDH were significant predictors of survival in Japanese patients with follicular lymphoma. Our predictive model may provide a basis for future therapeutic trials against follicular lymphoma in Japan.
日本滤泡性淋巴瘤的发病率远低于西方国家,且日本尚未针对该肿瘤开展大规模临床病理研究。我们回顾了1968年至1993年间被诊断为滤泡性淋巴瘤的135例患者中118例的组织病理学标本。采用单因素和多因素分析方法分析影响生存的预后因素。多因素分析中具有独立显著意义的因素被纳入预测模型。93例患者(78.8%)确诊为滤泡性淋巴瘤。其余25例患者中,21例被归类为其他淋巴瘤亚型,4例表现为不确定结果或提示非淋巴瘤疾病的结果。93例滤泡性淋巴瘤患者的主要特征为:中位年龄53岁(20 - 85岁);男性59例(63%),女性34例(37%);小裂细胞型33例(35%),混合细胞型41例(44%),大细胞型19例(20%);Ⅰ/Ⅱ期41例(44%),Ⅲ/Ⅳ期50例(54%)。5年总生存率为71%,10年为58%,15年为43%,中位生存期为13.3年。多因素分析显示,年龄(>60岁)(P = 0.001)和血清乳酸脱氢酶水平(>1倍正常值)(P = 0.026)这两个变量是影响生存的不良显著预后因素。使用这两个变量的预测模型确定了三个风险组,估计5年生存率分别为88.5%、56.8%和31.5%。年龄和血清乳酸脱氢酶是日本滤泡性淋巴瘤患者生存的显著预测因素。我们的预测模型可能为日本未来针对滤泡性淋巴瘤的治疗试验提供依据。